Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) have been given an average recommendation of “Moderate Buy” by the eight research firms that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $6.00.

A number of analysts recently weighed in on MRSN shares. Lifesci Capital upgraded Mersana Therapeutics to a “strong-buy” rating in a research note on Monday, July 29th. Robert W. Baird cut their price target on shares of Mersana Therapeutics from $4.00 to $3.00 and set a “neutral” rating for the company in a report on Wednesday, August 14th.

Institutional Investors Weigh In On Mersana Therapeutics

A number of large investors have recently bought and sold shares of the stock. ClariVest Asset Management LLC purchased a new stake in shares of Mersana Therapeutics in the first quarter valued at $2,114,000. Acadian Asset Management LLC raised its position in shares of Mersana Therapeutics by 166.7% in the first quarter. Acadian Asset Management LLC now owns 468,923 shares of the company’s stock valued at $2,099,000 after buying an additional 293,115 shares during the last quarter. Foundations Investment Advisors LLC purchased a new position in shares of Mersana Therapeutics during the fourth quarter valued at approximately $237,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Mersana Therapeutics during the first quarter worth approximately $226,000. Finally, Vanguard Group Inc. raised its holdings in Mersana Therapeutics by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 6,274,370 shares of the company’s stock valued at $28,109,000 after acquiring an additional 36,782 shares during the last quarter. Institutional investors and hedge funds own 93.92% of the company’s stock.

Mersana Therapeutics Price Performance

Shares of NASDAQ MRSN opened at $1.56 on Friday. The company has a current ratio of 3.51, a quick ratio of 3.51 and a debt-to-equity ratio of 0.72. The stock has a market cap of $190.88 million, a P/E ratio of -1.37 and a beta of 1.55. Mersana Therapeutics has a twelve month low of $1.07 and a twelve month high of $6.28. The stock has a 50 day moving average of $1.83 and a two-hundred day moving average of $3.03.

Mersana Therapeutics (NASDAQ:MRSN) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The firm had revenue of $2.30 million during the quarter, compared to analysts’ expectations of $8.72 million. Mersana Therapeutics had a negative net margin of 352.01% and a negative return on equity of 260.65%. The business’s quarterly revenue was down 78.3% on a year-over-year basis. During the same quarter last year, the business earned ($0.47) earnings per share. On average, research analysts forecast that Mersana Therapeutics will post -0.6 earnings per share for the current year.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.